Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 3961-3968

  Seo, Jae Hong ^a   Park, Jung Bae ^a   Choi, Woong Kee ^a   Park, Sunhwa ^a   Sung, Yun Jin ^a   Oh, Euichaul ^a   Bae, Soo Kyung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acid addition reaction; BCS class II; Besylate; Cilostazol; Dissolution; Mesylate

Indexed keywords

ANTITHROMBOCYTIC AGENT; BENZENE SULFONIC ACID; CHLORPROPAMIDE; CILOSTAZOL; CILOSTAZOL BESYLATE; CILOSTAZOL MESYLATE; METHANE SULFONIC ACID; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; BENZENESULFONIC ACID; BENZENESULFONIC ACID DERIVATIVE; CARDIOVASCULAR AGENT; MESYLIC ACID; MESYLIC ACID DERIVATIVE; TETRAZOLE DERIVATIVE;

ACID ADDITION REACTION; ADDITION REACTION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; PHOTOSTABILITY; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; RAT; STRESS STABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; WATER CONTENT; WETTABILITY; ANIMAL; BIOAVAILABILITY; BLOOD; COMPARATIVE STUDY; GASTROINTESTINAL ABSORPTION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BENZENESULFONATES; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; GASTROINTESTINAL ABSORPTION; MALE; MESYLATES; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TETRAZOLES; WETTABILITY;

EID: 84938322805     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S87687     Document Type: Article

References (24)

1. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des. 2003;9:2289–2302.
2. Shimizu T, Osumi T, Niimi K, Nakagawa K. Physico-chemical properties and stability of Cilostazol. Arzneimittelforschung. 1985;35:1117–1123.
3. Amidon GL, Lennernäs H, Shah VP, Crison JR. Theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.
4. Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet. 1999;37(suppl 2):S13–S23.
5. Kumar A, Sahoo SK, Padhee K, Kochar PS, Sathapathy A, Pathak N. Review on solubility enhancement techniques for hydrophobic drugs. Pharmacie Globale. 2011;3:001–007.
6. Sharma D, Soni M, Kumar S, Gupta GD. Solubility enhancement–eminent role in poorly soluble drugs. Res J Pharm Tech. 2009;2: 220–224.
7. Yellela SRK. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Availab. 2010;2: 28–36.
8. Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65:315–499.
9. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59:603–616.
10. Desai C, Prabhakar B. Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes. Drug Dev Ind Pharm. 2014;28:1–19.
11. Patel SG, Rajput SJ. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. AAPS Pharm Sci Tech. 2009;10:660–669.
12. Miao X, Sun C, Jiang T, Zheng L, Wang T, Wang S. Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol. J Pharm Pharm Sci. 2011;14:196–214.
13. Komasaka T, Fujimura H, Tagawa T, Sugiyama A, Kitano Y. Practical method for preparing nanosuspension formulations for toxicology studies in the discovery stage: formulation optimization and in vitro/in vivo evaluation of nanosized poorly water-soluble compounds. Chem Pharm Bull (Tokyo). 2014;62:1073–1082.
14. Mahmoud DB, Shukr MH, Bendas ER. In vitro and in vivo evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and parenteral administration. Int J Pharm. 2014;476:60–69.
15. Pund S, Shete Y, Jagadale S. Multivariate analysis of physicochemical characteristics of lipid based nanoemulsifying cilostazol-quality by design. Colloids Surf B Biointerfaces. 2014;115:29–36.
16. Patel SG, Rajput SJ, Groshev A, Sutariya VB. Preparation and characterization of microemulsion of cilostazol for enhancement of oral bioavailability. Curr Drug Deliv. 2014;11:531–540.
17. Park JH, Choi HK. Enhancement of solubility and dissolution of cilostazol by solid dispersion technique. Arch Pharm Res. 2015;38:1336–1344.
18. Elder DP, Delaney E, Teasdale A, et al. The utility of sulfonate salts in drug development. J Pharm Sci. 2010;99:2948–2961.
19. Branham ML, Moyo T, Govender T. Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement. Eur J Pharm Biopharm. 2012;80:194–202.
20. Paulekuhn GS, Dressman JB, Saal C. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. J Med Chem. 2007;50:6665–6672.
21. Callahan J, Cleary G, Elefant M, Kaplan G, Kensler T, Nash R. Equilibrium moisture content of pharmaceutical excipients. Drug Dev Ind Pharm. 1982;8:355–369.
22. Nokhodchi A, Al-Hamidi H, Antonijevic MD, Owusu-Ware S, Kaialy W. Dissolution and solid state behaviours of carbamazepine-gluconolactone solid dispersion powders: the potential use of gluconolactone as dissolution enhancer. Chem Eng Res Des. Epub 2015, May 11.
23. Varanasi KK, Sridhar V, Potharaju S, et al. Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;865:91–98.
24. Murikipudi V, Gupta P, Sihorkar V. Efficient throughput method for hygroscopicity classification of active and inactive pharmaceutical ingredients by water vapor sorption analysis. Pharm Dev Technol. 2013;18:348–358.